Meta-iodobenzylguanidine derivatives containing a second guanidine moiety Original Research Article

Radioiodinated meta-iodobenzylguanidine (MIBG) is used in the diagnosis and therapy of various neuroendocrine tumors. To investigate whether an additional guanidine function in the structure of MIBG will yield analogues that may potentially enhance tumor-to-target ratios, two derivatives—one with a guanidine moiety and another with a guanidinomethyl group at the 4-position of MIBG—were prepared. In the absence of any uptake-1 inhibiting conditions, the uptake of 4-guanidinomethyl-3-[131I]iodobenzylguanidine ([131I]GMIBG) by SK-N-SH cells in vitro was 1.7±0.1% of input counts, compared to a value of 40.3±1.4% for [125I[MIBG suggesting that guanidinomethyl group at the 4-position negated the biological properties of MIBG. On the other hand, 4-guanidino-3-[131I]iodobenzylguanidine ([131I]GIBG) had an uptake (5.6±0.3%) that was 12–13% that of [125I]MIBG (46.1±2.7%), and the ratio of uptake by control over DMI-treated (nonspecific) cultures was higher for [131I]GIBG (20.9±0.3) than [125I]MIBG itself (15.0±2.7). The exocytosis of [131I]GIBG and [125I]MIBG from SK-N-SH cells was similar. The uptake of [131I]GIBG in the mouse target tissues, heart and adrenals, as well as in a number of other tissues was about half that of [125I]MIBG. These results suggest that substitution of guanidine functions, especially a guanidinomethyl group, in MIBG structure may not be advantageous.